Loading…
Loading…
CRLBF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CRLBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for CRLBF and 80,000+ other tickers.
2 suppliers of Cresco Labs Inc., named in SEC filings, company releases and earnings calls, with the quote behind each one, the share of revenue where a filing gives it, and how it moved.
TapClick below to see what's inside, then upgrade to unlock it for CRLBF and every other company we cover.
See exactly how CRLBF's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CRLBF and 80,000+ other tickers.
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
Cresco Labs Inc. (CRLBF) Shareholder/Analyst Call Prepared Remarks Transcript
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Prestonsburg in Kentucky, the Company's 83rd dispensary nationwide. Sunnyside's opening marks a major milestone for Kentucky's emerging medical cannabis program, with dispensaries now operating in all 11 regions of the Commonwealth for the first time. “Access is the foundation of any successful medical cannabis program,” said Charlie Bac.
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Friday, November 6, 2026. The Company will host a conference call and webcast to discuss the results and provide inve.
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced that it has filed a supplement (the "Supplement") to its management information circular dated September 18, 2026 (the "Circular") in connection with its annual general and special meeting of shareholders to be held on October 30, 2026. The Supplement enhances and clarifies the disclosure in the Circular concerning the proposed amendment to Cresco's super-voting shares a.
The marijuana industry is entering another important period for investors as September 2026 gets underway. Cannabis stocks have experienced significant volatility over the past several years. However, several major operators continue building their businesses despite challenging industry conditions.